Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  De Bandt, Michel ^a   Fautrel, Bruno ^b   Maillefert, Jean F ^c   Berthelot, Jean M ^d   Combe, Bernard ^e   Flipo, René Marc ^f   Lioté, Frédéric ^g   Meyer, Olivier ^h   Saraux, Alain ⁱ   Wendling, Daniel ^j   Le Loët, Xavier ^k   Guillemin, Francis ^l,m  

^a Centre hospitalier d'Aulnay sous Bois   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL DU BOCAGE   (France)

^d HÔTEL DIEU   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g CENTRE VIGGO PETERSEN   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^k ROUEN UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF NANCY   (France)

^m UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

28 JOINT DISEASE ACTIVITY SCORE; ADULT; ARTICLE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; JOINT SWELLING; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHYSICIAN; PUBLIC HEALTH; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; CLINICAL PRACTICE; PRACTICE GUIDELINE; RHEUMATOLOGY; STANDARD;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY;

EID: 75649084215     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2836     Document Type: Article

References (24)

1. Grigor C, Capell H, Stiring A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269. 10.1016/S0140-6736(04)16676-2, 15262104.
2. Verstappen SM, Jacobs JW, Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW, . Utrecht Rheumatoid Arthritis Cohort study group Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449. 10.1136/ard.2007.071092, 17519278, Utrecht Rheumatoid Arthritis Cohort study group.
3. Combe B, Landewe R, Lukas C, Bolosiu H, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:34-45. 10.1136/ard.2005.044354, 16396980.
4. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308-1315. 10.1002/art.1780241012, 7306232.
5. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005, 64:1294-1298. 1755664, 15829574, 10.1136/ard.2004.030924.
6. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007, 66(Suppl 3):iii2-iii22. 10.1136/ard.2007.081430, 17934088.
7. Khanna D, Oh M, Furst DE, Ranganath V, Gold RH, Sharp JT, Park GS, Keystone EC, Paulus HE, . Western Consortium of Practicing Rheumatologists Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007, 57:440-447. 10.1002/art.22619, 17394230, Western Consortium of Practicing Rheumatologists.
8. Wells G, Boers M, Tugwell P, . MDA Working Group Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S52-S59. MDA Working Group.
9. Pincus T, Kavanaugh A, Aletaha D, Smolen J. Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S1-S6.
10. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252-1255. 10.1093/rheumatology/keh297, 15238643.
11. Mäkinen H. Is DAS28 an appropriate tool to assess remission in patients with RA. Ann Rheum Dis 2005, 64:1410-1413. 1755218, 15941836, 10.1136/ard.2005.037333.
12. Heijde DM, van 't Hof M, van Riel PL, Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581.
13. Meyer O, de Bandt M, Berthelot JM, Cantagrel A, Combe B, Fautrel B, Flipo RM, Lioté F, Maillefert JF, Saraux A, Wendling D, Guillemin F, Le Loët X, . Working Group for Therapeutic Strategies for Rheumatoid Arthritis Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. Joint Bone Spine 2007, 74:73-78. 10.1016/j.jbspin.2006.05.008, 17194614, Working Group for Therapeutic Strategies for Rheumatoid Arthritis.
14. Le Loët X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B, Flipo RM, Lioté F, Maillefert JF, Meyer O, Saraux A, Wendling D, Guillemin F. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006, 65:45-50. 1797976, 15994280, 10.1136/ard.2005.035436.
15. Fautrel B, Guillemin F, Meyer O, De Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X. Clinical practice preference-based decision tree for the choice of the second-line disease modifying antirheumatic drug in rheumatoid arthritis after the failure of the first treatment: a proposal from the French Society of Rheumatology. Arthritis Care Res 2009, 61:425-434.
16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
17. Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK, Combe B, Badsha H, Drosos AA, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Burmester GR, Tunc R, Dimiæ A, Nedoviæ J, Stankoviæ A, Bergman M, Toloza S, Pincus T, . Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008, 58:2642-2651. 10.1002/art.23794, 18759292, Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group.
18. Kapral T, Dernoschnig F, Machold KP, Stamm T, Schoels M, Smolen JS, Aletaha D. Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. Arthritis Res Ther 2007, 9:R72. 2206375, 17662115, 10.1186/ar2270.
19. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions?. Clin Exp Rheumatol 2006, 24(6 Suppl 43):S45-S51.
20. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landewé RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Heijde DM, van Riel PL, Wolfe F, Tugwell PS. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005, 32:2016-2024.
21. Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol 2005, 32:2025-2029.
22. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, Heijde D, Wells G, Dougados M. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007, 34:1188-1193. 2760122, 17477485.
23. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007, 21:789-804. 10.1016/j.berh.2007.02.009, 17678835.
24. Furst D, Halbert R, Bingham C, Fukudome S, Anderson L, Bonafede P, Bray V, Cohen S, Sherrer Y, St Clair E, Tesser J, Weinblatt, Dubois R. Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. Rheumatology (Oxford) 2008, 47:194-199. 10.1093/rheumatology/kem326, 18178593.